Key result
Roux-en-Y bariatric surgery linked to ~33% reduction in BMI over 12 months.
Why the study?
Obesity is a major modifiable cardiovascular risk factor and the effects of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and inflammation in obese patients with and without diabetes require evaluation.
Does Roux-en-Y bariatric surgery improve lipoproteins, insulin resistance, and systemic and vascular inflammation in obese patients with and without diabetes?
Cohort (n=37)
No
Does Roux-en-Y bariatric surgery improve lipoproteins, insulin resistance, and systemic and vascular inflammation in obese patients with and without diabetes?
Effect estimate: Partial eta squared 0.49
Absolute Event Rate: 35% vs 52%
p-value: p=<0.0001
Roux-en-Y bariatric surgery significantly improves cardiometabolic and inflammatory markers in obese patients, with the majority of improvements occurring within the first 6 months.
Purpose: Obesity is a major modifiable risk factor for cardiovascular disease. Bariatric surgery is considered to be the most effective treatment option for weight reduction in obese patients with and without type 2 diabetes. Objective: To evaluate changes in lipoproteins, insulin resistance, mediators of systemic and vascular inflammation and endothelial dysfunction following Roux-en-Y bariatric surgery in obese patients with and without diabetes. Materials and methods: Lipoproteins, insulin resistance, mediators of systemic and vascular inflammation, and endothelial dysfunction were measured in 37 obese patients with (n=17) and without (n=20) type 2 diabetes, before and six and twelve months after Roux-en-Y bariatric surgery. Two way between subject ANOVA was carried out to study the interaction between independent variables (time since surgery and presence of diabetes) and all dependent variables Results: There was a significant effect of time since surgery on (large effect size) weight, BMI, waist circumference, TG, sdLDL ApoB, HOMA-IR, CRP, MCP-1, ICAM-1, E selectin, P selectin, leptin and adiponectin. BMI and waist circumference had the largest impact of time since surgery. The effect of time since surgery was noticed mostly in the first 6 months. Absence of diabetes led to a significantly greater reduction in TC, LDL-C and nonHDL-C although the effect size was small to medium. There was a greater reduction in TG and HOMA-IR in patients with diabetes with a small effect size. No patients were lost to follow up. Conclusion: Lipoproteins, insulin resistance, mediators of systemic and vascular inflammation, and endothelial dysfunction improve mostly 6 months after bariatric surgery in obese patients with and without diabetes. ClinicalTrials.gov Identifier: NCT02169518 https://clinicaltrials.gov/ct2/show/NCT02169518?term=paraoxonase&cntry1=EU%3AGB&rank=1
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2017) conducted a cohort in Obesity with and without type 2 diabetes (n=37). Roux-en-Y bariatric surgery vs. Baseline (pre-surgery) was evaluated on Body mass index (Partial eta squared 0.49, p=<0.0001). Roux-en-Y bariatric surgery significantly reduced body mass index from a baseline of 52 to 35 kg/m2 (p<0.0001) and improved insulin resistance and inflammatory markers over 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: